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Abstract: The contribution of candidate genetic variants involved in azathioprine biotransformation
on azathioprine e cacy and pharmacokinetics in 111 young patients with inflammatory bowel
disease was evaluated. Azathioprine doses, metabolites thioguanine-nucleotides (TGN) and
methylmercaptopurine-nucleotides (MMPN) and clinical e↵ects were assessed after at least 3 months
of therapy. Clinical e cacy was defined as disease activity score below 10. Candidate genetic
variants (TPMT rs1142345, rs1800460, rs1800462, GSTA1 rs3957357, GSTM1, and GSTT1 deletion)
were determined by polymerase chain reaction (PCR) assays and pyrosequencing. Statistical analysis
was performed using linear mixed e↵ects models for the association between the candidate variants
and the pharmacological variables (azathioprine doses and metabolites). Azathioprine metabolites
were measured in 257 samples (median 2 per patient, inter-quartile range IQR 1-3). Clinical e cacy
at the first evaluation available resulted better in ulcerative colitis than in Crohn’s disease patients
(88.0% versus 52.5% responders, p = 0.0003, linear mixed e↵ect model, LME). TGN concentration and
the ratio TGN/dose at the first evaluation were significantly higher in responder. TPMT rs1142345
variant (4.8% of patients) was associated with increased TGN (LME p = 0.0042), TGN/dose ratio (LME
p < 0.0001), decreased azathioprine dose (LME p = 0.0087), and MMPN (LME p = 0.0011). GSTM1
deletion (58.1% of patients) was associated with a 18.5% decrease in TGN/dose ratio (LME p = 0.041)
and 30% decrease in clinical e cacy (LME p = 0.0031). GSTA1 variant (12.8% of patients) showed a
trend (p = 0.046, LME) for an association with decreased clinical e cacy; however, no significant e↵ect
on azathioprine pharmacokinetics could be detected. In conclusion, GSTs variants are associated
with azathioprine e cacy and pharmacokinetics.
Keywords: azathioprine; inflammatory bowel disease; glutathione-S transferase; pharmacogenetics;
pharmacokinetics
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1. Introduction
Inflammatory bowel disease (IBD) is a chronic, relapsing and remitting disease of the
gastrointestinal tract that comprises two main entities, Crohn’s disease (CD) and ulcerative colitis
(UC). The disease has a peak onset in subjects 15 to 30 years old, and its incidence is rising in the
pediatric population [1]. Despite the recent introduction in therapy of biologicals, thiopurines continue
to be widely used in this disease; indeed, these are cheap drugs, and maintain at least 20% of patients
in a state of stable long term steroid free clinical remission [2]. Among thiopurines, azathioprine
is mainly used as an immunosuppressant in IBD, and, although it has a well described risk benefit
profile, adverse drug reactions are relatively common, occurring in 15–18% of patients, and can be
severe enough to require the withdrawal of therapy [3,4] In addition, a significant proportion of
patients does not respond to therapy with this agent [5–7]. The reasons of this high heterogeneity in
clinical response is not clear yet [8]; however, variability in azathioprine metabolism can be important;
indeed, azathioprine is a prodrug that requires metabolic conversion to its active form. The first step
in this metabolic conversion is mediated by conjugation with glutathione, resulting in the formation
of mercaptopurine. This reaction is in part nonenzymatic but it is even controlled, as demonstrated
by recent publications, by the enzyme glutathione S-transferase (GST in particular by the isoforms A
and M [9]. The latter is also inactive and is converted by the enzymes of the purine salvage pathway
to the active thioguanine nucleotides, which are responsible of the cytotoxic and apoptotic e↵ect of
these drugs [10]. Mercaptopurine is metabolized by the enzyme xanthine oxidase in the liver, and
by thiopurine methyltransferase (TPMT) and inosine triphosphatase (ITPA), mainly in extra hepatic
tissues [10]. Polymorphisms in genes involved in azathioprine metabolism can hence influence the
e cacy and toxicity of this drug [6].
In this study, we aimed to evaluate the contribution of candidate genetic variants involved in
azathioprine biotransformation on azathioprine e cacy and pharmacokinetics in young patients
with IBD.
2. Materials and Methods
2.1. Patient Characteristics
111 patients with IBD were enrolled by the Gastroenterology Unit of the Pediatric Hospital “Burlo
Garofolo” in Trieste, Italy between March 2004 and February 2015. The study was conducted in
accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional
Ethics Committee (Projects RC 23/2005 and 12/2013). All subjects and parents gave their informed
consent for inclusion before they participated in the study. The inclusion criteria were age less than
30 years, previous diagnosis of IBD and treatment with azathioprine for at least 3 months. The patients
enrolled are all the patients taking azathioprine at “Burlo Garofolo” in Trieste in the time-frame of the
study. Blood samples for azathioprine metabolites measurement and for genotyping were taken at the
appropriate clinic visit. Timing of metabolite level measurement was determined by the clinical setting
of azathioprine administration at the hospital: generally, azathioprinemetabolites levels weremeasured
after 3, 6, and 12 months of treatment and then every year. Patients were treated with a dose-escalating
strategy to reduce the risk of adverse events starting, however, from a relatively high dose (median of
2 mg/kg). At subsequent follow-up visits (every 3 months), the dose was increased or reduced so as to
obtain the optimal clinical response; the criteria used to increase or reduce the dose of azathioprine
were the level of disease activity and laboratory parameters used to monitor azathioprine toxicity
(in particular leukocyte, erythrocyte and platelet counts, hemoglobin concentration, mean corpuscular
volume, liver enzymes alanine aminotransferase, aspartate aminotransferase and -glutamyltransferase,
and amylase levels). According to current guidelines, genotyping information was shared with the
clinicians only for patients presenting TPMT variant alleles, in order to allow increased monitoring of
adverse events.
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Clinical response was assessed using Pediatric Crohn’s Disease Activity Index and Pediatric
Ulcerative Colitis Activity Index, respectively [11], for CD and UC patients at the time of blood sample
collection for the first metabolites’ measurement, which occurred at least 3 months since the beginning
of therapy. The disease was considered inactive if the disease activity index was <10 at the time of
sample collection.
2.2. Measurement of Azathioprine Metabolites
Metabolites (TGNandMMPN)weremeasured inpatients’ erythrocytes using thehighperformance
liquid chromatography assay by Dervieux and Boulieu [12]. The ratio between TGN and the dose of
azathioprine was calculated considering, for each individual measurement of the metabolites, the dose
the patients took the day the blood sample was recorded.
2.3. Genotypes
Genomic DNAwas extracted from peripheral blood samples using a commercial kit (Sigma, Milan,
Italy), to characterize genetic polymorphisms in the candidate genes TPMT (rs1142345, rs1800460 and
rs1800462), GSTA1 (rs3957357), GSTM1 (deletion), and GSTT1 (deletion). The considered genotypes
and method of analysis are described in Table 1. Genotypes for TPMT rs1800462 was determined
by polymerase chain reaction (PCR) with allele specific oligonucleotides (ASO). Primers used were,
for the wild-type allele, as forward P2W 50-GTATGATTTTATGCAGGTTTG-30 and as reverse P2C
50-TAAATAGGAACCATCGGACAC-30; primers. For the variant allele, a second tube was used
with P2M 50-GTATGATTTTATGCAGGTTTC-30 as forward primer and the above-mentioned P2C
50-TAAATAGGAACCATCGGACAC-30 as reverse. PCR protocol for these primers were: initial
denaturation 5 min at 94  C, followed by 37 cycles with 30 s at 94  C, 30 s at 57  C, and 2 min at
72  C, with a final extension for 10 min at 72  C. PCR product was visualized on a 2% agarose gel.
In case of a patient carrying the wild type allele, the product (254 bp) was present with the P2W
and P2C primers; in case of patients carrying the variant allele, with the P2M and P2C primers for
TPMT rs1800460 and rs1142345, PCR- restriction fragment length polymorphism (RFLP) was used. For
rs1800460, primers used were: forward 50-AGGCAGCTAGGGAAAAAGAAAGGTG-30 and reverse
50-CAAGCCTTATAGCCTTACACCCAGG-30. PCR protocol for these primers was: initial denaturation 5
min at 94  C, followed by 37 cycleswith 30 s at 94  C, 30 s at 55  C, and 2min at 72  C,with a final extension
for 10 min at 72  C. The DNA amplification produces an amplicon of 694 bp, which is subsequently
digested enzymatically with the enzyme Mwol (concentration of 1 U/10 µl) incubated for 90 min at 60
 C. The enzyme recognizes the wild-type site and cuts the DNA strand into two fragments of 443 bp
and 251 bp, while it does not cut the variant fragment. A 2% agarose gel was prepared for visualization.
For rs1142345, primers used were forward 50-AATCCCTGCTGTCATTCTTCATAGTATTT-30 and reverse
50-CACATCATAATCTCCTCTCC-30. PCR protocol was the same as TPMT rs1800460. PCR produces a
401 bp amplicon, which is subsequently digested enzymatically with the Accl enzyme (concentration 1
U/10 µl) and incubated for 90 min at 37  C. The enzyme recognizes the variant site and cuts the DNA
strand into two 252 pb and 149 pb fragments while the wild-type strand is not cut. A 2% agarose gel was
prepared for visualization. GSTM1 and GSTT1 genotypes were determined by MULTIPLEX-PCR-ASO
as previously described [13], in which three pairs of primers were used simultaneously: a specific
pair for the T isoform, one for the M isoform and one for the  -globin gene, which acts as an internal
positive control in order to verify the amplification. The three pairs of primers lead to three fragments
of different sizes: 480 bp (GSTT), 286 bp ( -globin), and 219 bp (GSTM). The primers used have
the following sequence: GSTM Forward: 50-GAACTCCCTGAAAAGCTAAAGC-30; GSTM Reverse:
50-GTTGGGCTCAAATATACGGTGC-30;  -GlobinForward: 50-GAAGAGCCAAGGACAGGT-30;  -Globin
Reverse: 50-CAACTTCATCCACGTTCACC-30; GSTT Forward: 50-TTCCTTACTGGTCCTCACATCTC-30;
GSTT Reverse: 50-TCACCGGATCATGGCCAGCA-30. PCR protocol for these primers were: initial
denaturation 5 min at 94  C, followed by 37 cycles with 30 s at 94  C, 30 s at 57  C, and 2 min at 72  C,
with a final extension for 7 min at 72  C. All PCR reactions described were carried out using RedTaq
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polymerase (Sigma, Milan, Italy), with the addition of dNTPs 0,25 nM and with a primer concentration of
1 mM.
Table 1. Assay used for genotyping of the considered variants.
Gene
Polymorphism
rs Number Primary Locus Alleles [14] Genotyping Method
TPMT
rs1800462 C > G missense PCR-ASO [13]
rs1800460 C > T missense PCR-RFLP [13]
rs1142345 T > C missense PCR-RFLP [13]
GSTM1 No rs number Deletion MULTIPLEX-PCR-ASO [13]
GSTT1 No rs number Deletion MULTIPLEX-PCR-ASO [13]
GSTA1 rs3957357 A > G (50-UTR) Pyrosequencing [15]
ASO: allele specific oligonucleotides; GST: glutathione-S-transferase, TPMT: thiopurine-S-methyl transferase; RFLP:
restriction fragment length polymorphism. PCR: polymerase chain reaction.
For GSTA1, pyrosequencing was employed (Table 1), since this genotyping method was
already validated in the laboratory. The primers used for the pyrosequencing were: forward
50-ATCCAGTAGGTGGCCCCTTG-30, reverse 50-ACCGTCCTGGCTCGACAA-30 (biotinylated).
Sequencing primer was: 50-GCTTTTCCCTAACTTGAC-30. PCR protocol for these primers were: initial
denaturation 10 min at 95  C, followed by 40 cycles with 30 s at 95  C, 30 s at 66  C, and 30 s at 72  C
and with a final extension for 10 min at 72  C. PCR produces a 148 bp amplicon. For pyrosequencing,
we used PSQ96MA (Qiagen, Hilden, Germany). PCR amplifications were performed in an Eppendorf
Mastercycler gradient, with TaqGold DNA Polymerase (AB Applied Biosystems, Foster City, CA, USA).
2.4. Statistical Analysis
Statistical analysis was performed using the software R (version 2.15). The association between
pharmacological phenotypes of interest (i.e., clinical e cacy of treatment, dose of azathioprine, TGN
metabolites concentrations, MMPN metabolites concentrations, ratio TGN/dose) and the considered
demographic variables, IBD type, cotreatment or genotypes in a univariate analysis, was evaluated
using linear mixed e↵ects model built using the phenotype as the dependent variable, each covariate
as the fixed e↵ect and the patients as the random e↵ect in the model. For clinical e cacy, the first
availablemeasurementwas used, while for other pharmacological variables, all availablemeasurements
were used.
Multivariate analysis was carried out to test the independence of the e↵ects of the genotypes
significant in the univariate analysis on the phenotypes considered (i.e., TGN or MMPN concentrations,
dose of azathioprine, ratio TGN/dose); for this multivariate analysis generalized linear models of the
Gaussian family were used considering individually each phenotype from the univariate analysis as
the dependent variable and the covariates significant in the univariate analysis as the independent
variables. Normality of the phenotype was tested by the Shapiro test and log10 transformation was
applied if needed, in order to adjust the normality of the distribution.
3. Results
3.1. Patients Enrolled and Samples Collected
111 patients were enrolled from March 2004 to February 2015; median age was 15.05 years (IQR
12.28–16-82), 52 (46.8%) were females. Clinical and demographic characteristics of the enrolled patients
are reported in Table 2.
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Table 2. Demographic and clinical characteristics of the patients enrolled in the study.
All Patients (n = 111)
Age (Years) at Time of Sample Collection 15.1, 12.3–16.8
Gender
Female (%) 52 (46.8%)
Male (%) 59 (53.2%)
Type of IBD Crohn’s disease (%) 61 (55.0%)
Ulcerative colitis (%) 50 (45.0%)
Length (days) of treatment with azathioprine 533, 245–917
For continuous variables, median, 1st–3rd quartiles values are reported. To report age and length of treatment
median and interquartile range are provided; for patients with more than one measurement of azathioprine
metabolites, median age and length of treatment were used.
Azathioprine metabolites were measured in 257 samples (median 2 per patient, IQR 1-3). Among
these, 89 were obtained during treatment with azathioprine alone and 161 during treatment with
azathioprine and other medications and in particular: 93 with an aminosalicylate, 18 with an
aminosalicylate and a glucocorticoid, 15 with infliximab, 10with an antibiotic, 4 with an aminosalicylate
and an antibiotic, 4 with an antibiotic and a glucocorticoid, 3 with an aminosalicylate, an antibiotic
and a glucocorticoid, 2 with an infliximab and a glucocorticoid, and 1 with an aminosalicylate and
infliximab; for 7 patients, information about concomitant treatment could not be retrieved.
3.2. Measurement of Azathioprine Metabolites: Association with Demographic and Clinical Covariates
Results of measurements together with azathioprine dose are shown in Table 3.
Table 3. Summary of azathioprine’s dose and metabolites’ concentrations.
TGN
(pmol/8 ⇥ 10ˆ8
Erythrocytes)
MMPN
(pmol/8 ⇥ 10ˆ8
Erythrocytes)
Dose (mg/kg)
TGN/Dose
((pmol/8 ⇥ 10ˆ8
Erythrocytes)/(mg/kg))
Mean 361.6 1698.1 2.0 192.8
Median 345.0 1044.0 2.1 179.4
Interquartile range 240.1–465.1 431.2–2079.7 1.7–2.3 120.1–227.9
MMPN indicated methylated nucleotides, TGN indicates thioguanine nucleotides.
Concentration of TGN metabolites were associated with IBD type, with UC patients showing
slightly increased concentrations (Supplementary Figure S1, LME p = 0.047), but not with gender or
treatment length. Azathioprine dose was strongly associated with age, with younger patients taking
higher doses (Supplementary Figure S2, LME p = 0.0001), but not with gender, IBD type or treatment
length. Concentration of MMPNmetabolites or the ratio between TGN concentration and azathioprine
dose were not associated with IBD type, gender, or treatment length. Interestingly, the ratio between
TGN concentration and azathioprine dose was strongly associated with azathioprine dose when the
analysis was limited to pediatric patients (i.e., with age less than 18, Supplementary Figure S3, LME
p = 0.0043). Clinical e cacy, defined as disease activity score below 10 at the time of first sample
collection for measurement of azathioprine metabolites, was assessed in all patients. Azathioprine
was more e↵ective in UC than in CD patients (88.0% versus 52.5% responders, LME p = 0.0003), while
gender, age, and duration of azathioprine treatment were not associated with azathioprine e cacy.
A higher concentration of TGNmetabolites at the first evaluation was observed in patients in remission
(Figure 1, LME p = 0.0099), similarly a positive correlation was observed with TGN/dose ratio (Figure 1,
LME p = 0.0023).
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Figure 1. Response to azathioprine (AZA) and thioguanine nucleotides (TGN) concentration, as
pmol/8 ⇥ 10ˆ8 erythrocytes (left panel) or ratio between TGN concentration/daily azathioprine dose as
pmol/8 ⇥ 10ˆ8 erythrocytes/mg/kg/day (right panel). p-values are from linear mixe e↵ect model (LME).
On the contrary, azathioprine dose and the concentration ofMMPNmetaboliteswere not associated
with a clinical response (data not shown).
3.3. Genotyping
Results of genotyping are reported in Table 4.
Table 4. Genotype distribution in the 111 patients enrolled in the study.
Gene
Polymorphism Genotyping Result
rs Number Wild-Type Hetero-zygous HomozygousVariant
Not
Available
p-value Hardy
Weinberg
TPMT rs1800462 105 (100%) 0 0 6 NA
TPMT rs1800460 101 (97.1%) 3 (2.9%) 0 7 0.88
TPMT rs1142345 0 (95.2%) 5 (4.8%) 0 6 0.81
GSTA1 rs3957357 38 (44.2%) 37 (43.0%) 11 (12.8%) 25 0.77
Gene Polymorphism
Genotyping Result
Not Deleted Deleted Not Available
GSTM1 Deletion 42 (41.9%) 61 (58.1%) 8
T Deletion 78 (75.7%) 25 (24.3%) 8
GST indicates glutathione-S-transferase, TPMT indicates thiopurine-S-methyl transferase.
All polymorphisms evaluated respectedHardy-Weinberg equilibrium and their distributionwas in
accordance with literature data for subjects of Caucasian ethnicity. For the association between genetic
variants and azathioprine pharmacokinetics, TPMT rs1142345 variant (4.8% of patients) was associated
with increased TGN (LME p = 0.0042), TGN/dose ratio (LME p < 0.0001), decreased azathioprine dose
(LME p = 0.0087) and MMPN (LME p = 0.0011; Figure 2), as well established [2]. Interestingly, all
patients with variant TPMT were in remission at the first evaluation of thiopurine metabolites, in
comparison to 65% of patients with wild-type TPMT (LME p = 0.041, Figure 2).
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Figure 2. TPMT rs1142345 and azathioprine (AZA)dose, thioguanine (TGN) andmethylmercaptopurine
(MMPN) metabolites and e cacy. Concentration of azathioprine metabolites is expressed as
pmol/8 ⇥ 10ˆ8 erythrocytes (U). p-values are from linear mixed e↵ect model (LME).
GSTM1 deletion (58.1% of patients) was associated with a 18.5% decrease in TGN/dose ratio (L E
p = 0.041, Figure 3) and 30% decrease in clinical e cacy (LME p = 0.0031; Figure 3). Additionally,
MMPN was reduced in patients with deletion of GSTM1 (LME p = 0.039; Figure 3).
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Figure 3. GSTM1deletion andazathioprine (AZA)dose, thioguanine (TGN), andmethylmercaptopurine
(MMPN) metabolites and e cacy. Concentration of azathioprine metabolites is expressed as
pmol/8 ⇥ 10ˆ8 erythrocytes (U). p-values are from linear mixed e↵ect model (LME).
GSTA1 variant (12.8% of patie ts) showed a tr nd for an ass ciation with decreased clinical
e cacy (LME p = 0.046, Figure 4); however, no significant e↵ect on azathi prine pharmacokinetics
could be detected (Figure 4).
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Figure 4. GSTA1 rs3957357 variant and azathioprine (AZA) dose, thioguanine (TGN) and
methylmercaptopurine (MMPN) metabolites and e cacy. Concentration of azathioprine metabolites is
expr ssed as mol/8 ⇥ 10ˆ8 erythrocytes (U). p-valu s are from linear mixed e↵ect model (LME).
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GSTT1 deletion was not associated with azathioprine pharmacokinetics and e cacy (data not
shown). Multivariate analysis supported the results of the univariate analysis (Table 5).
Table 5. Multivariate analysis considering for each pharmacological dependent variable covariate
significant in the univariate analysis.
Azathioprine Related
Pharmacological Phenotype
(Dependent Variable)
Independent Variable in
Multivariate Generalized
Linear Model
Comparison E↵ect p-Value
E cacy of azathioprine at the
first metabolite measurement
IBD type UC versus CD 1.96 0.0019
GSTM1 genotype Deletion versus Normal  1.49 0.019
GSTA1 genotype AA versus GG/GA  1.30 0.095
TPMT genotype AG versus GG 24.7 0.43
TGN metabolites
concentrations
IBD type UC versus CD 0.061 0.074
TPMT genotype AG versus GG 0.23 0.0049
MMPN metabolites
concentration
GSTM1 genotype Deletion versus Normal  0.21 0.014
TPMT genotype Heterozygous versus wild-type  0.72 0.0004
Azathioprine dose Age Each year  0.035 <0.0001
TPMT genotype Heterozygous versus wild-type  0.58 0.0056
Ratio TGN/dose TPMT genotype Heterozygous versus wild-type 0.41 0.0001GSTM1 genotype Deletion versus Normal  0.072 0.055
GST: glutathione-S-transferase, IBD: inflammatory bowel disease, UC: ulcerative colitis, CD: Crohn’s disease,
MMPN: methylated nucleotides, TGN: thioguanine nucleotides, TPMT: thiopurine-S-methyl transferase. The e↵ect
size represents the increase (positive value) or decrease (negative value) in the value of the dependent variable for
each independent variable listed. p-values are from linear mixed-e↵ect models.
4. Discussion
Despite the introduction of new and e↵ective biologics in the therapy of IBD, the thiopurine
drugs azathioprine and mercaptopurine continue to be frequently used for maintaining remission in
these diseases. The problem with these drugs is that they are ine↵ective in a significant percentage of
patients, and also induce side e↵ects that can be severe [2]. The reasons for this variability are not clear;
however, a number of studies have suggested that variations in enzymes involved in their metabolism
can be involved.
For azathioprine, this agent is the prodrug of mercaptopurine, and has to be converted to produce
its pharmacological activity. This conversion can occur spontaneously, but is also catalyzed by the
enzymes GST, in particular the A and M isoforms [16]. In rat liver homogenates, Kaplowitz et al. have
demonstrated that, while at high pH (pH = 8.0) the nonenzymatic and enzymatic reactions occur at
similar levels, at pH closer to physiological values, the enzymatic reaction prevails [17]. In addition, in
homogenates of human livers obtained from transplant donors, treatment with furosemide, an inhibitor
of soluble GSTs [18], inhibited the conversion of azathioprine to mercaptopurine [19]. Additional
evidence of a role of GSTs in azathioprine metabolism has been obtained in animal models; indeed,
pretreatment of rats with the GST inhibitor probenecid increased the proportion of azathioprine in
rat liver and reduced GSH consumption. Similarly, less hepatic GSH depletion was observed after
azathioprine treatment in Gunn rats, a model of hyperbilirubinemic rat [17]. Of interest, bilirubin is
also a GST inhibitor, with some studies indicating a stronger inhibitory e↵ect of bile acids on GSTM1 in
comparison to other isoforms [20].
We previously showed that the frequency of GSTM1 deletion was significantly lower in patients
that developed an adverse event in comparison to patients that tolerated azathioprine treatment, in
agreement with a model in which patients with GSTM1 deletion are less sensitive to the e↵ects of
azathioprine, putatively because of the contribution of this enzyme on the conversion of azathioprine
to mercaptopurine [13]. Moreover, in a recent previous study [21], we evaluated the e↵ects of GST
polymorphisms on azathioprine biotransformation in a cohort of young patients with IBD, tolerant
to azathioprine therapy and taking the drug for more than 3 months. Patients with the deletion of
GSTM1 tolerated a dose of azathioprine significantly higher in comparison to patients with normal
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GSTM1. Moreover, the amount of active TGNs generated in patients with the deletion of GSTM1
was significantly decreased in comparison to patients with a normal genotype. Multivariate analysis
confirmed that this e↵ect was independent from that of other genes with a significant e↵ect, such as
TPMT, the main gene known to influence mercaptopurine metabolism [22].
The present study is the first report of an association between azathioprine e cacy andGSTM1 and
GSTA1 variants in young patients with IBD. Moreover, we confirmed the reduced TGN/azathioprine
dose ratio in patients with GSTM1 deletion we previously reported, which may be associated with the
described lower e cacy of azathioprine in patients with this genotype. This could support the need
for genotype adjusted tailored therapy, possibly testing the e cacy of strategies leading to higher TGN
concentration in patients with GSTM1 deletion, such as increased azathioprine dose or co-treatment
with an aminosalycilate [23], even if prospective studies are needed to further support these strategies.
Therefore, all these studies support a role of GSTM1 on azathioprine e cacy, mediated by an
increased conversion of azathioprine to mercaptopurine. The reaction catalyzed by GSTM1 likely
occurs after oral administration mainly in the intestine and the liver, modulating the amount of
mercaptopurine and TGNs that are released in the main circulation [24].
Azathioprine dose is strongly associated with patients’ age in the present study, an observation
consistent with our previous results in children with IBD, showing that these patients require higher
doses of azathioprine to achieve similar therapeutic e cacy and TGN concentration [25]. TPMT activity
indeed is significantly higher in children than in adults [26]; interestingly, in pediatric patients (age less
than 18 years), we could observe a lower ratio of TGN/azathioprine dose, as in our previous report.
However, when the analysis was extended to young adults (age less than 30 years), the correlation
between age and the TGN/dose ratio was lost. This may be related to environmental factors, including
epigenetic determinants, even if more studies are needed to elucidate the mechanisms underlying
these observations [27].
Considering studies by other groups, our results are in agreement with a recently published
paper describing a lower e cacy of azathioprine in patients with GSTM1 deletion, even if the results
were not fully significant [28]. Moreover, in our study, we observed reduced concentration of MMPN
nucleotides during azathioprine treatment in patients with GSTM1 deletion: this result is consistent
with a recent study by Broekman et al. [29]; this study also supports a lack of e↵ect of GSTA1 variants
on azathioprine TGN and MMPN concentrations. The clinical implications of these observations need
to be further explored. Additionally, age may a↵ect the association of GSTs variants with thiopurine
e↵ects; indeed, studies in adult patients could not identify a consistent e↵ect of GSTM1 variants
on thiopurines induced adverse e↵ects [30], and therefore, other studies in the pediatric population
are needed.
A recent study investigated the association among GST polymorphism, enzyme activity and
azathioprine-related adverse drug reactions in Chinese Han patients with IBD, finding that the patients
who became neutropenic had a significantly higher GSTs activity when compared with patients who
did not develop toxicity [31]. The authors found, in the univariate analysis, that GSTM1 wildtype
genotype had a relationship with leukopenia and flue like symptoms, whileGSTP1 variant was strongly
associated with leukopenia. Following adjustment for other potential risk factors, it was shown that
GSTP1 variants only were associated with increased risks of leukopenia. In our current study, we
did not consider the e↵ect of GSTP1 polymorphisms on azathioprine e↵ects and metabolism, since
in our previous studies no significant association with adverse e↵ect [13] or biotransformation [21]
could be detected. The lack of association may be due to the tissue distribution of GSTP1 and GSTT1,
which are not highly expressed in the liver, but even to the lack of specific activity of these enzymes
toward the catalysis of the reaction of azathioprine with glutathione [9,16]. Since the GSTP isoform
does not catalyze the biotransformation of azathioprine to mercaptopurine [16], other mechanisms
could be involved in the association observed by Liu and collaborators, such as induction of oxidative
stress or modulation of apoptosis [24]. The study by Liu et al. reporting an e↵ect of GSTP1 variants
on azathioprine induced adverse events, with a milder e↵ect of GSTM1, seems to underline that the
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e↵ects of GSTs on azathioprine pharmacogenetics may be influenced by ethnicity. Indeed, it is already
known that variants frequent in Asian patients but uncommon in other ethnic groups, are associated
with increased sensitivity to thiopurines, such asMRP4 and NUDT15 [32,33].
One limitation of our study is its retrospective design and the consequent di culty of properly
assessing phenomena such as drug interaction, which should rely on data collection from patients’
charts. Drug interactions between azathioprine and other agents employed in IBD have been described;
in particular, a significant decrease in TGN levels after discontinuation of aminosalicylates has been
previously reported [23]. Moreover, for GSTA1, a marginal e↵ect on thiopurine e cacy was observed
but this was not supported by an e↵ect on thiopurine pharmacokinetics: this may be related to
the limited number of patients homozygous for the GSTA1 variant enrolled. Another limitation is
the fact that the current assay for thiopurine metabolites quantifies two main species (thioguanine
nucleotides andmethyl-mercaptopurine nucleotides), without distinguishing betweenmonophosphate,
diphosphate, and triphosphate nucleotides. Innovative mass spectrometry based assays are now
available to quantify thiopurine metabolites [34], allowing quantification of phosphorylation of
thionucleotides [35] and they could be applied to evaluate di↵erences in thiopurine biotransformation
in patients with various GST genotypes. Evaluation of the combined e↵ects of genotypes in this
study is limited. Indeed, multivariate analysis indicates independency in the e↵ects of the candidate
genotypes considered on the pharmacological variables in the present cohort. A larger cohort is needed
to detect significant e↵ects by combined genotypes. For demographic covariates, in particular gender,
no significant e↵ect was identified in the univariate analysis; to further evaluate interactive e↵ect of
gender and the considered genotypes, a larger cohort is needed.
In conclusion, GSTs variants were associated with azathioprine e cacy and pharmacokinetics;
more studies, both clinical and molecular are still needed to apply this evidence to improve outcomes
of therapy with azathioprine in young patients with IBD.
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